Viaskin Peanut data sufficient for BLA

DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) said Wednesday that FDA has agreed that the available safety and efficacy data for peanut allergy candidate Viaskin Peanut (DBV-712) will support a BLA submission for the product. DBV plans to submit the BLA in 2H18.

The news sent DBV shares up €9.04 (27%) to €41.94 on Euronext and $5.37 (26%) to $26.23 on NASDAQ...